Prediction of Clinical Response After 1 Year of Infliximab Therapy in Rheumatoid Arthritis Based on Disease Activity at 3 Months: Posthoc Analysis of the RISING Study
| Autor: | Takao Koike, Toru Yoshinari, Nobuyuki Miyasaka, Toshiro Yano, Tohru Abe, Tsutomu Takeuchi, Takashi Inui |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male Infliximab therapy medicine.medical_specialty Immunology Severity of Illness Index Gastroenterology Arthritis Rheumatoid Disease activity Rheumatology Internal medicine medicine Dose escalation Humans Immunology and Allergy In patient Dosing business.industry Remission Induction Middle Aged medicine.disease Infliximab Surgery Treatment Outcome Antirheumatic Agents Rheumatoid arthritis Treatment strategy Female business medicine.drug |
| Zdroj: | The Journal of Rheumatology. 42:599-607 |
| ISSN: | 1499-2752 0315-162X |
| DOI: | 10.3899/jrheum.140572 |
| Popis: | Objective.To investigate the probability of clinical remission (REM) or low disease activity (LDA) after 1 year of infliximab (IFX) therapy based on disease activity at 3 months in patients with rheumatoid arthritis (RA).Methods.Methotrexate-refractory patients with RA received 3 mg/kg of IFX at weeks 0, 2, and 6, followed by 3 mg/kg, 6 mg/kg, or 10 mg/kg every 8 weeks from Week 14 (W14) to Week 46. Correlation of disease activity at W14 with disease activity at W54 and probability of REM/LDA at W54 were analyzed in each dosing group.Results.Disease activities at W14 were significantly correlated with both disease activity at W54 and probability of REM/LDA at W54 in patients continuing 3 mg/kg as well as in those receiving 6 mg/kg or 10 mg/kg therapy from W14. Results showed that, if approximate REM or LDA had not been achieved by W14, > 50% of patients continuing 3 mg/kg therapy would not be able to achieve REM or LDA at W54. However, even in patients with high or moderate disease activity at W14, dose escalation to 6 mg/kg or 10 mg/kg enabled many to achieve REM/LDA.Conclusion.Disease activity at W14 in standard-dose IFX therapy enabled the prediction of longterm clinical response at continued standard dose, as well as subsequent escalated-dose regimens. Disease activity at W14 was hypothesized to be an important index for IFX treatment strategy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|